Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (101-110 of 155) with videos related to

Pageof 16
Sort By:
Leukemia Research|May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activityIan W Flinn, John C Byrd, Nancy Bartlett, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.
Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Pageof 16

Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
Leukemia Research|May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activityIan W Flinn, John C Byrd, Nancy Bartlett, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.
Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Pageof 16